As far as we can tell, Vivos Inc (OTCMKTS:RDGLD) is a proposition that demands more meat on the bone. The action has been lively in recent days, though, as one can plainly see. To help further flesh out the story, the company just announced that its certified veterinarian treated its first patient, a cat named Drake.
According to the release, “the patient has already been released since this is same-day therapy. Drake’s spindle cell sarcoma had been treated previously with external beam therapy but the tumor reoccurred. In this therapy, Dr. Meyer focused on treating the margins around the tumor to reduce the chance of re-occurrence. The pet’s owner is a veterinarian from Sitka Alaska. He had researched the options and decided that IsoPet was his best choice to extend the life of his cat.”
Vivos Inc (OTCMKTS:RDGLD) bills itself as a pharmaceutical company researching and developing minimally invasive treatments to combat cancer in humans and animals. It has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet) and in humans (Radiogel).
Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPet is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at the University of Missouri is currently underway.
The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet is classified as a device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet to University animal hospitals and private veterinary clinic consortiums.
IsoPet for treating animals uses the same technology as RadioGel for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
The Company is also engaging the FDA for premarket clearance to market RadioGel for the treatment of advanced basal and squamous cell skin cancers in humans.
Find out when $RDGLD reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, RDGLD just announced that its certified veterinarian treated its first patient, a cat named Drake.
We’ve witnessed above 200% piled on for shareholders of the stock during the trailing month. In addition, the company has seen a growing influx of trading interest, with the stock’s recent average trading volume running a bit over 220% above the average volume levels in play in this stock over the longer term.
Dr. Mike Korenko stated “This therapy is the culmination of more than two years of dedicated work to bring Isopet to market. We will be screening patients for future therapies. The current pricing for Isopet is competitive with external beam therapy, with the advantage that Y-90 IsoPet can deliver much higher doses in a single treatment and is precision targeted with insignificant collateral damage to healthy tissue. Over time and as patient volumes increases, we will continue to work to reduce production costs to significantly expand our customer base.” Isopet provides certified veterinarians with an on-demand next generation cancer therapy alternative without the significant capital expenditure associated with traditional beam therapy. Pet owners who choose Isopet will know that this important expenditure provides their pet with a powerful new treatment that can dramatically enhance quality of life without the need for the repeated treatment typically required by traditional beam therapy.”
Now commanding a market cap of $9.5M, RDGLD has about $50k in cash on the books, which is balanced by about $1.1M in total current liabilities. The company is pre-revenue at this point. We will update the story again as soon as further details emerge. Sign-up for continuing coverage on shares of $RDGLD stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $RDGLD, either long or short, and we have not been compensated for this article.